These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1367 related items for PubMed ID: 9402652

  • 1. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T, Behrendt N, Ploug M.
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [Abstract] [Full Text] [Related]

  • 2. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ, Lee SW, Dichek DA, Ellis V.
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [Abstract] [Full Text] [Related]

  • 3. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
    Jardí M, Inglés-Esteve J, Burgal M, Azqueta C, Velasco F, López-Pedrera C, Miles LA, Félez J.
    Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T.
    BMC Cell Biol; 2006 Feb 20; 7():8. PubMed ID: 16504015
    [Abstract] [Full Text] [Related]

  • 5. Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
    Saldanha RG, Molloy MP, Bdeir K, Cines DB, Song X, Uitto PM, Weinreb PH, Violette SM, Baker MS.
    J Proteome Res; 2007 Mar 20; 6(3):1016-28. PubMed ID: 17330942
    [Abstract] [Full Text] [Related]

  • 6. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K.
    J Lab Clin Med; 2004 Aug 20; 144(2):69-77. PubMed ID: 15322501
    [Abstract] [Full Text] [Related]

  • 7. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG, Pass J, Illemann M, Høyer-Hansen G, Lund IK.
    J Immunol Methods; 2008 Nov 30; 339(1):55-65. PubMed ID: 18761343
    [Abstract] [Full Text] [Related]

  • 8. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
    Chavakis T, Kanse SM, May AE, Preissner KT.
    Biochem Soc Trans; 2002 Apr 30; 30(2):168-73. PubMed ID: 12023845
    [Abstract] [Full Text] [Related]

  • 9. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
    Behrendt N, Rønne E, Danø K.
    Biol Chem Hoppe Seyler; 1995 May 30; 376(5):269-79. PubMed ID: 7662169
    [Abstract] [Full Text] [Related]

  • 10. Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate.
    Elfman F, Bok R, Conn M, Shuman M, Cunha G.
    Differentiation; 2001 Dec 30; 69(2-3):108-20. PubMed ID: 11798065
    [Abstract] [Full Text] [Related]

  • 11. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM, Zappala M, Zheng M, Yu L, Wilkins-Port C, McKeown-Longo PJ.
    Matrix Biol; 2007 Jun 30; 26(5):359-70. PubMed ID: 17344041
    [Abstract] [Full Text] [Related]

  • 12. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug 30; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 13. Regulation of urokinase receptor function and pericellular proteolysis by the integrin alpha(5)beta(1).
    Bass R, Ellis V.
    Thromb Haemost; 2009 May 30; 101(5):954-62. PubMed ID: 19404550
    [Abstract] [Full Text] [Related]

  • 14. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE, Saunders DN, Ranson M.
    Breast Cancer Res; 2007 May 30; 9(1):R14. PubMed ID: 17257442
    [Abstract] [Full Text] [Related]

  • 15. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, Dong JH, Li X.
    Clin Cancer Res; 2007 Jun 01; 13(11):3115-24. PubMed ID: 17545513
    [Abstract] [Full Text] [Related]

  • 16. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
    Conese M, Blasi F.
    Biol Chem Hoppe Seyler; 1995 Mar 01; 376(3):143-55. PubMed ID: 7612191
    [Abstract] [Full Text] [Related]

  • 17. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 18. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.
    Xue W, Mizukami I, Todd RF, Petty HR.
    Cancer Res; 1997 May 01; 57(9):1682-9. PubMed ID: 9135008
    [Abstract] [Full Text] [Related]

  • 19. Down-regulation of integrin alpha M beta 2 ligand-binding function by the urokinase-type plasminogen activator receptor.
    Tang ML, Kong LS, Law SK, Tan SM.
    Biochem Biophys Res Commun; 2006 Sep 29; 348(3):1184-93. PubMed ID: 16905120
    [Abstract] [Full Text] [Related]

  • 20. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
    Saldanha RG, Xu N, Molloy MP, Veal DA, Baker MS.
    J Proteome Res; 2008 Nov 29; 7(11):4792-806. PubMed ID: 18808175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.